Venetoclax Add-On Improves Complete Remission in AML

A phase 2 study found 91% complete remission in patients with AML who received venetoclax plus standard therapy. The study was published as a preprint and has not yet been peer reviewed.

Related Keywords

China ,Zhejiang ,Huafeng Wang ,Entrepreneur Team Introduction Program Of Zhejiang ,National Natural Science Foundation Of China ,Zhejiang University School Of Medicine ,European Leukemianet ,Leading Innovative ,Entrepreneur Team Introduction Program ,National Natural Science Foundation ,First Line Therapy ,Adult Patients With Acute Myeloid Leukemia ,Zhejiang University School ,Acute Leukemia ,Acute Myeloblastic Leukemia ,Hematology ,Chemotherapy ,Physician Assistants ,Anthracyclines ,Neoadjuvant ,Peer Review ,Young Adult ,